86482-18-0

Activity is that of ticarcillin , the role of the inhibitor being to restore the activity against β-lactamase-producing strains that would otherwise hydrolyze the drug.

C_max 3 g ticarcillin + 100 mg: 330 mg/L end: 8 mg/L end
clavulanate intravenous: infusion: infusion
infusion (30 min)
Plasma half-life: 1.1 h 1.1 h
Plasma protein binding: 45% 25%
The pharmacokinetics of the two agents are mutually unaffected by co-administration. Ticarcillin can be detected in tissues and interstitial fluid following parenteral administration. Penetration into bile, peritoneal fluid and pleural fluid has been demonstrated. Concentrations in blister fluid were significantly lower than those in serum.
Around 60–70% of ticarcillin and 35–45% of clavulanic acid are excreted unchanged in urine during the first 6 h after administration of a single dose of the mixture.

Septicemia, including bacteremia
Lower respiratory infections
Bone and joint infections
Skin and skin structure infections
Urinary tract infections (complicated and uncomplicated)
Gynecological infections, endometritis
Intra-abdominal infections, peritonitis
Its main use is in infections in which Ps. aeruginosa is suspected or proven.

Adverse reactions associated with ticarcillin occur . As with co-amoxiclav, there is a risk of cholestatic jaundice . Pseudomembranous colitis has been reported.